Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Schweiger, M; Romauch, M; Schreiber, R; Grabner, GF; Hütter, S; Kotzbeck, P; Benedikt, P; Eichmann, TO; Yamada, S; Knittelfelder, O; Diwoky, C; Doler, C; Mayer, N; De, Cecco, W; Breinbauer, R; Zimmermann, R; Zechner, R.
Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice.
Nat Commun. 2017; 8:14859 Doi: 10.1038/ncomms14859 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Eichmann Thomas
Grabner Gernot
Kotzbeck Petra
Schreiber Renate
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Elevated circulating fatty acids (FAs) contribute to the development of obesity-associated metabolic complications such as insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). Hence, reducing adipose tissue lipolysis to diminish the mobilization of FAs and lower their respective plasma concentrations represents a potential treatment strategy to counteract obesity-associated disorders. Here we show that specific inhibition of adipose triglyceride lipase (Atgl) with the chemical inhibitor, Atglistatin, effectively reduces adipose tissue lipolysis, weight gain, IR and NAFLD in mice fed a high-fat diet. Importantly, even long-term treatment does not lead to lipid accumulation in ectopic tissues such as the skeletal muscle or heart. Thus, the severe cardiac steatosis and cardiomyopathy that is observed in genetic models of Atgl deficiency does not occur in Atglistatin-treated mice. Our data validate the pharmacological inhibition of Atgl as a potentially powerful therapeutic strategy to treat obesity and associated metabolic disorders.
Find related publications in this database (using NLM MeSH Indexing)
Adipose Tissue, White - enzymology
Animals - administration & dosage
Body Weight - drug effects
Diet, High-Fat - administration & dosage
Fatty Liver - blood, drug therapy, enzymology, prevention & control
Feeding Behavior - administration & dosage
Glucose - metabolism
Homeostasis - drug effects
Humans - administration & dosage
Insulin Resistance - administration & dosage
Lipase - antagonists & inhibitors, metabolism
Lipolysis - drug effects
Male - administration & dosage
Mice, Inbred C57BL - administration & dosage
Obesity - drug therapy, enzymology, pathology
Phenylurea Compounds - pharmacology, therapeutic use

© Med Uni Graz Impressum